EvaluatePharma Vision’s new enhancement, Product Specific PTRS, gives you a unique view of the likelihood of approval for any NME or NDA product across every stage of the development process.
Watch the video for a quick overview and fill in the form below to find out more.
In addition, other valuable new EvaluatePharma Vision enhancements include the ability to quickly identify products expected to be first to market; tailored views of the R&D pipeline through interactive visualizations; and the first comprehensive analysis of R&D trial costs based on real world data.
Don’t just know pharma, Evaluate it.
Thanks for your interest in Evaluate
EvaluatePharma Vision offers a unique view of the risk and reward of the R&D landscape that’s valued by everyone from the top 25 global pharma companies to growing biotechs or medtechs, to leading investment banks and smaller management consultancies.
EvaluatePharma Vision is fully integrated with EvaluatePharma, so you can view all of the R&D risk and reward metrics available alongside market leading consensus forecasts in a single view.
Probability of technical and regulatory success is also known as the likelihood of approval and is the probability of a product achieving FDA approval from its current phase, based on the individual probabilities of progressing through each stage of development.
EvaluatePharma Vision’s Product Specific PTRS covers 9,500+ NME & NDA drug R&D programs and is the only transparent product specific success rate model, providing unique insight into the predictive power of individual risk attributes, enabling differentiated decision making.